Becton Dickinson and Co (NYSE:BDX) Stock Holdings Increased by Jacobs & Co. CA

Jacobs & Co. CA increased its holdings in Becton Dickinson and Co (NYSE:BDX) by 5.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,228 shares of the medical instruments supplier’s stock after purchasing an additional 1,539 shares during the quarter. Becton Dickinson and accounts for 1.3% of Jacobs & Co. CA’s holdings, making the stock its 27th biggest position. Jacobs & Co. CA’s holdings in Becton Dickinson and were worth $8,121,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Ronna Sue Cohen raised its holdings in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after acquiring an additional 5,710,365 shares during the period. Thoroughbred Financial Services LLC raised its holdings in shares of Becton Dickinson and by 25,302.2% during the second quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock valued at $99,094,000 after acquiring an additional 987,039 shares during the period. FMR LLC raised its holdings in shares of Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock valued at $4,453,934,000 after acquiring an additional 842,590 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock valued at $1,103,526,000 after acquiring an additional 416,459 shares during the period. Finally, Intermede Investment Partners Ltd acquired a new stake in shares of Becton Dickinson and during the second quarter valued at approximately $76,019,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Becton Dickinson and stock traded down $4.11 during trading hours on Wednesday, hitting $249.23. The company had a trading volume of 108,682 shares, compared to its average volume of 1,214,724. The firm has a market capitalization of $68.66 billion, a price-to-earnings ratio of 22.64, a P/E/G ratio of 1.85 and a beta of 1.11. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. The company’s fifty day moving average is $252.03. Becton Dickinson and Co has a fifty-two week low of $208.62 and a fifty-two week high of $265.87.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. The firm had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.91 EPS. As a group, analysts expect that Becton Dickinson and Co will post 11.68 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.24%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s dividend payout ratio is 27.97%.

BDX has been the topic of a number of recent analyst reports. Raymond James boosted their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a report on Friday, June 28th. Piper Jaffray Companies cut their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Wells Fargo & Co cut their price target on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. Finally, Barclays upgraded shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target on the stock in a report on Monday, May 13th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus price target of $264.27.

In other Becton Dickinson and news, insider James C. Lim sold 1,929 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $252.01, for a total value of $486,127.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Samrat S. Khichi sold 16,085 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the sale, the executive vice president now directly owns 12,608 shares of the company’s stock, valued at $2,958,845.44. The disclosure for this sale can be found here. Insiders sold 24,529 shares of company stock valued at $5,836,116 over the last three months. Insiders own 0.12% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Call Option

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.